Some of these changes have been characterized to provide a clear contribution to the development and/or progression of the cancer and include overexpression of HER2/neu in about 20% of breast cancer [1], and hereditary mutations in BRCA1 or BRCA2 in approximately 5% of breast cancers [2]. This evidence concerns the gene ERBB2 and cancer.